The Investigators hypothesize that older red cell units trigger phagocytosis and activation of circulating macrophages with a downstream immunomodulatory cascade and release of excess Non Transferrin Bound Iron(NTBI) that leads to increased rates of infection in adults with Sickle Cell Disease(SCD).
To test this hypothesis, the study staff will perform a randomized prospective clinical trial. In aim 1, the study staff will determine the biochemical differences between ≥30 day-old versus ≤10 day-old units. In aim 2, the study staff will determine the physiologic effects of the transfused blood in a patient with SCD. Lastly, in aim 3, the study staff will explore the clinical implications of receiving older red cells over a 3 month period.
| Matthew Karafin, MD | |
| 414-937-6809 | |
| [email protected] |
| David Wichlan | |
| 919-966-6876 | |
| [email protected] |
3 United States sites
16 Years - 60 Years
Phase 2/Phase 3
Interventional
All
Biological
age 16 to 60 years
Hemoglobin SS/Hemoglobin Sβ-thalassemia^0
on chronic red cell transfusion therapy
outpatient at the time of transfusion
history of reactions to transfusion therapy that cannot be adequately managed by antihistamines
≥ 2 red cell alloantibodies
participation in another therapeutic trial for SCD
pregnant
HIV positive
uncontrolled inter-current illness, or psychiatric illness/social situations that would limit compliance with study requirements.